1. Introduction

Cadmium (Cd) is a non-essential metal present at position 7 on the substance priority list of the Agency for Toxic Substances and Disease Registry (ATSDR 2019). Mainly, it is an environmental and industrial toxicant, derived from incineration, refining, mining, and fossil fuel combustion. Environmental exposure to Cd is progressively increasing, owing to the wide use of Cd-containing goods in industrialized countries, and it represents a major public health risk due to its non-biodegradability as well as to its long biological half-life (10–30 years) [1].

Environmental Cd may accumulate in many organs, such as liver, lung, testes, and bones. However, the main target of Cd is considered the kidney, particularly the proximal renal tubules, and increased glutathione (GSH) content and glutathione peroxidase (GPx) activity. Moreover, Cd caused damages to glomeruli and tubules, and increased expression of Nrf2, Nqo1, and Hmox1 gene expression. Cur, Re and BJe at 40 mg/kg significantly improved all parameters, while BJe at 20 mg/kg showed a lower protective effect. After treatment with the associations of the three nutraceuticals, all parameters were close to normal, thus suggesting a new potential strategy in the protection of renal functions in subjects exposed to environmental toxics.
tubules and renal glomeruli [2,3], where it accumulates, owing to the absence of a specific mechanism for elimination. Indeed, after chronic exposure to Cd, approximately 50% of the total body stores accumulate in the kidneys [4], making them particularly susceptible to Cd-mediated nephrotoxicity.

After having been absorbed by the organism, Cd binds to metallothionein, a cysteine-rich, low-molecular weight metal-binding protein [5]. The complex Cd-metallothionein is filtered into the Bowman’s space by the glomerular capillaries and internalized by the proximal tubule cells. The complex is then degraded by lysosomes to release Cd [6]. In the cytoplasm, the release of Cd is known to produce reactive oxygen species (ROS), cause glutathione (GH) exhaustion, lipids peroxidation, protein crosslinking, and inflammation. As a result, an accumulation of pro-inflammatory cytokines and kidney cell death occur, leading to kidney toxicity [6,7].

Further mechanisms of Cd renal toxicity have been also described: among them, mitochondrial damage [8], cellular death, in particular apoptosis induction [9], disruption of cadherin-mediated cell-cell adhesion in the proximal tubule cells [10], and stimulation of the inflammation pathways [11] were observed.

Currently, there is no effective treatment for Cd poisoning. The principal therapeutic protocol involves employment of metal chelator, although they cause several undesirable effects, such as redistribution/translocation of metals and other serious toxic manifestations [12]. This caught the interest of scientists who have sought for an effective remedy from natural sources, that are less prone to toxic effects. In recent years, several natural products have been proposed to prevent structural and functional damages following environmental or experimental Cd exposure, with particular attention to the protective functions of plant-derived antioxidants such as carnosic acid [13], chocolate [14], grape seed procyanidin [15], alphalipoic acid [16], flavocoxid [17] and myo-inositol [18].

In the last decades, bergamot juice (BJ), obtained from Citrus bergamia Risso et Poiteau (bergamot) fruits, has attracted the attention of scientist on antioxidant natural products [19,20]. Indeed, it has been shown that BJ and its flavonoid-rich fraction (BJe) exert several biological activities, among which anti-cancer [21], anti-infective [22,23], hypolipemic and hypoglycemic [24], neuroprotective [25,26], antioxidant [27,28] and anti-inflammatory effects [29–32]. Moreover, very recently, we showed that BJe reduces the testicular damage induced by Cd through a mechanism involving its anti-inflammatory and anti-apoptotic activities [33].

Curcumin (Cur) or diferuloylmethane (1,7-bis(4-hydroxy-3-methoxyphenyl)-16-heptadiene-3,5-dione) is a hydrophobic polyphenol extracted from the rhizome of Curcuma longa L., commonly known as turmeric. Its protective effect on kidney damage, associated with its antioxidant, anti-inflammatory and anti-tumorigenesis properties, has been broadly described in several experimental models [34,35].

Resveratrol (Re; 3,5,4′-trihydroxy-trans-stilbene), is a naturally occurring polyphenol found mainly in in the skin of grapes, in berries, and peanuts. Re has been studied for its pharmacological effects, including antioxidant, anti-inflammatory, immunomodulatory, hepatoprotective, anti-cancer, anti-atherosclerotic, and anti-diabetic properties [36–39].

On these bases, the present study was designed to investigate the effects of the nutraceuticals BJe, Cur, and Re, alone or in association, in a murine model of Cd-induced kidney damage.

2. Materials and Methods

2.1. Ethical Approval

All the experiments were conducted in conformity with the Italian Guidelines for Care and Use of Laboratory Animals (D.L.116/92) and with the European Directive (2010/63/EU), as well as in compliance with the ARRIVE (Animal Research Reporting In Vivo Experiments) guidelines. The study was approved by the National Ethics Committee for Research Animal Welfare of the Italian Ministry of Health (authorization no. 112/2017-
PR, 2 February 2017) and by the Institutional Animal Care and Use Ethic Committee of the University of Messina (OPBA, #820/2016, 2 September 2016).

2.2. Drugs and Chemicals

The BJe used in this research was already used in our previous research [21,33,40]. Its quali-quantitative analysis showed that neohesperidin (94.00 mg/g), naringin (92.4 mg/g), melitidin (56.2 mg/g), hesperetin (51.9 mg/g), neoeviciotin (48.6 mg/g) and naringenin (27.3 mg/g) were the most abundant flavonoids. Cadmium chloride (CdCl₂) was purchased from Sigma-Aldrich Srl (Milan, Italy). All other chemicals not listed were commercially available reagent grade.

2.3. Experimental Protocol

A total of 119 adult male C57 BL/6J mice, weighing 25–30 g, were acquired from Charles River Laboratories Italia Srl (Calco, LC, Italy) and housed at the animal facility of the School of Medicine of the University of Messina, Messina, Italy. The animals were fed with a standard diet ad libitum with free access to tap water under a 12-h light/dark cycle. The animals were randomly included in 17 groups of 7 mice each. Nine groups were used as control (i) 0.9% NaCl (vehicle); (ii) corn oil (vehicle); (iii) Cur (50 mg/kg); (iv) Cur (100 mg/kg); (v) Re (20 mg/kg); (vi) BJe (20 mg/kg); (vii) BJe (40 mg/kg); (viii) Cur (50 mg/kg) + Re (20 mg/kg) + BJe (20 mg/kg); (ix) Cur (100 mg/kg) + Re (20 mg/kg) + BJe (40 mg/kg), while 8 groups were treated as follows: (i) CdCl₂ (2 mg/kg) + vehicle; (ii) CdCl₂ + Cur (50 mg/kg); (iii) CdCl₂ + Cur (100 mg/kg); (iv) CdCl₂ + Re (20 mg/kg); (v) CdCl₂ + BJe (20 mg/kg); (vi) CdCl₂ + BJe (40 mg/kg); (vii) CdCl₂ + Cur (50 mg/kg) + Re (20 mg/kg) + BJe (20 mg/kg); (viii) CdCl₂ + Cur (100 mg/kg) + Re (20 mg/kg) + BJe (40 mg/kg). CdCl₂, Re, and BJe were dissolved in 0.9% NaCl; Cur was dispersed in corn oil. The oral administration of Cur, Re, and BJe and intraperitoneal (i.p.) challenge with CdCl₂ was performed for 14 days. The doses of all substances employed were selected in accordance with previous studies [17,18,21,33,40–46]. Twenty-four hours after the last treatment, all mice were sacrificed with an overdose of ketamine and xylazine (75/10 mg/kg i.p. each) and bilateral nephrectomies were performed. The kidneys were processed for molecular, histological, and immunohistochemical evaluation. A graphical scheme of the study design is reported in Figure 1.

Figure 1. Graphical scheme of the study design. The dose of CdCl₂ was 2 mg/kg, while those of Cur, Re and BJe are expressed as mg/mL.
2.4. Urea Nitrogen and Creatinine Levels Quantification

After clotting, blood samples were centrifuged and urea nitrogen was quantified by a colorimetric kit (Roche Diagnostics GmbH, Mannheim, Germany), following manufacturer’s guidelines [17]. Creatinine levels were evaluated by an enzymatic method with an automatic analyzer (Roche Diagnostics GmbH).

2.5. Determination of Glutathione (GSH) and Glutathione Peroxidase (GPx) Content

GSH content was measured in the kidneys of all groups according to Ellman’s (1959) method, as recommended by Gong and co-workers [47]; while, glutathione peroxidase (GPx) was evaluated according to Flohé and Günzler [48], as detailed by Manna and collaborators [49].

2.6. Real-Time PCR Analyses

Total RNAs from kidney samples from animals of all challenged groups were extracted with the TRIzol LS reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s guidelines. Then, 2 µg of RNA from each sample were reverse transcribed into cDNA using the High-Capacity cDNA Archive Kit (Applied Biosystems, Life Technologies, Foster City, CA, USA). The mRNA expression was evaluated by Real-time PCR, as previously described [21]. The sequences of primer employed for the real-time PCR analyses are listed in Table 1. The Real-time PCRs were carried out in 20 µL reactions containing 1xSYBR® Select Master Mix (Applied Biosystems), 0.2 µM of primers, and 25 ng RNA converted into cDNA. The analyses were performed in triplicate in a 96-well plate using a 7900HT Fast Real-Time PCR System (Applied Biosystems). Data were collected and analyzed using the $2^{-\Delta\Delta CT}$ relative quantification method with β-actin (Actb) used as endogenous control. The values are presented as fold changes relative to the control tissues.

Table 1. Oligonucleotide primers used for the quantitative Real-time PCR analyses.

| Gene  | Protein                  | NCBI Reference Sequence | Primer Sequence                      |
|-------|--------------------------|-------------------------|--------------------------------------|
| Actb  | Beta-actin               | NM_007393.5             | F: GCTGTGCTATGTTGCTCTTA              |
|       |                          |                         | R: TCGTTGCAAATATGATGATGA             |
| Bax   | Apoptosis regulator BAX  | NM_007527.3             | F: GCGAATTGGAGATGAACCTA              |
|       |                          |                         | R: CAGTGGAAGTTGCAATCA                |
| Bcl2  | Apoptosis regulator Bcl-2| NM_009741.5             | F: GTGGAGGAACCTCTTCAGG               |
|       |                          |                         | R: TGACATCTCCCTGTCGAC                |
| Hmox1 | Heme oxygenase 1         | NM_002133.3             | F: GCCTCTCTGCTCAACAT                 |
|       |                          |                         | R: ACGGAATGACGCCCATG                 |
| Il1b  | Interleukin-1 beta       | NM_008361.4             | F: ACACCTACGTTGCTGTAATGAA           |
|       |                          |                         | R: GCCTCTCCTTGACCTTTGA               |
| Nos2  | Nitric oxide synthase, inducible | NM_010927.4 | F: GCCGAGGTGTTGATGGTTG               |
|       |                          |                         | R: GCAGCCCTCTGTCTTTGA                |
| Nqo1  | NAD(P)H dehydrogenase [quinone] 1 | NM_009706.5 | R: TCAGATCATCCCTCCAGCTC              |
|       |                          |                         | F: TCAAACCGCCTTCAAGAATG             |
| Nrf2  | Nuclear factor erythroid 2-related factor 2 | NM_010902.4 | R: GCCAACACATGGCATCCTG                |
|       |                          |                         | F: TGAAAGACAGGCAGACCT                 |
|       |                          |                         | R: ACTTGTAGTGAGTTTG                  |
| Tp53  | Tumor suppressor p53     | NM_001127233.1          |                                      |

2.7. Histological Evaluation

The kidneys were fixed in freshly prepared Bouin solution, dehydrated in graded ethanol, cleared in xylene, and embedded in paraffin (Paraplast, SPI Supplies, West Chester, PA, USA). Five-micrometer sections were stained with hematoxylin and eosin (HE) and periodic acid-Schiff (PAS). The slides were photographed with a Nikon Ci-L (Nikon Instruments, Tokyo, Japan) light microscope by a digital camera Nikon Ds-Ri2, and saved as Joint Photographic Experts Group (JPEG) with the software Adobe Photoshop 2021 (Adobe, San Jose, CA, USA).
2.8. Immunohistochemical Analysis for IL-1β and Nrf2

Paraffin-embedded 5-µm sections, derived from the same specimens used for histological evaluation, were assembled on Polysine slides (Thermo Fisher Scientific, Waltham, MA, USA), cleared in xylene and rehydrated in ethanol. Antigen retrieval was achieved with citrate buffer (pH 6.0) and endogenous peroxidase was stopped with 0.3% H2O2 in phosphate buffer saline (PBS). Primary antibodies IL-1β (1:250, Santa Cruz Biotechnology, Dallas, TX, USA) and Nrf2 (1:150, St. John’s Laboratory, London, UK) were incubated overnight at 4 °C in a moisturized chamber. The day after, the secondary antibodies (Vectastain, Vector, Burlingame, CA, USA) were added and 3,3′-Diaminobenzidine (DAB) (Sigma-Aldrich) was used to visualize the reaction. The sections were counterstained with Mayer’s hematoxylin. Appropriate positive and negative controls were used in each test. Slides were photographed with a Nikon Ci-L light microscope using a digital camera Nikon Ds-Ri2.

2.9. Morphometric Evaluation

Two trained investigators (DP and AM) blindly performed all quantitative evaluations. The mean glomerular area (TGA), expressed in square micrometers (µm²), was calculated from ten HE-stained sections of each group, measuring twenty glomeruli of the cortical region with the Image J software (National Institute of Health, Bethesda, MD, USA) [50]. Tubular damage was assessed according to a previously described method [18,51]. Briefly, twenty micrographs from PAS-stained sections of each group were studied and evaluated according to the following score: 0 = undamaged; 0.5 = reduction of the brush border with or without interstitial edema; 1 = lower tubular epithelial cells with or without interstitial edema; 2 = incomplete presence of the tubular epithelium with or without interstitial edema; 3 = tubular necrosis with interstitial edema.

A morphometric study to quantitatively assess IL-1β and Nrf2 expression was also performed with ImageJ software. The RGB color images were converted in 32-bit grayscale images, using the function Image > type > 32-bit. A unit area (UA) of 200 × 200 µm, including only tubules, was selected and the grayscale values of twenty UAs of each group were calculated in optical units (OU) from 0 = black to 255 = white. With this method, a higher expression of IL-1β and Nrf2 corresponded to darker images and was reported as lower values in the 0–255 grayscale; a lower expression of IL-1β and Nrf2 was indicated by lighter images, corresponding to higher values on the same scale.

2.10. Statistical Analysis

Values are expressed as mean ± standard error (SE). The statistical significance of differences between groups was established using the Student’s t-test. The statistical evaluation of differences among groups was performed with ANOVA comparison test. The statistical analysis of histological scores was performed using Mann–Whitney U test with Bonferroni correction. A p-value of ≤ 0.05 was considered statistically significant.

3. Results

3.1. Effects of Nutraceuticals on Urea Nitrogen and Creatinine Levels

Levels of urea nitrogen and creatinine are often employed as biomarkers for the evaluation of kidney function. In our study, no significant differences in urea nitrogen and creatinine levels were observed in the serum of all control groups; therefore, only one value is indicated for controls (Table 2). Urea nitrogen and creatinine levels were significantly increased in CdCl2-challenged mice, compared to control groups (p < 0.05). In CdCl2-challenged animals co-treated with all tested nutraceuticals, urea nitrogen and creatinine levels were lower than CdCl2 + vehicle group (p < 0.05), being similar to control mice in those treated with BJe at the dose of 40 mg/kg and with both associations (CdCl2 + Cur 50 mg/kg + Re 20 mg/kg + BJe 20 mg/kg and CdCl2 + Cur 100 mg/kg + Re 20 mg/kg + BJe 40 mg/kg).
Table 2. Effects on urea nitrogen and creatinine levels in control mice, in cadmium chloride (CdCl$_2$; 2 mg/kg i.p.) plus vehicle exposed ones and in those exposed to CdCl$_2$ (2 mg/kg i.p.) co-administered with curcumin (Cur), resveratrol (Re), bergamot juice extract (BJe), or their combinations. All values are expressed as mean $\pm$ SE; $n=7$ animals for each group.

| Treatment | Urea Nitrogen (mg/dL) | Creatinine (mg/dL) |
|-----------|-----------------------|--------------------|
| Controls  | 14.5 ± 1.7            | 0.68 ± 0.1         |
| CdCl$_2$ + vehicle | 41.2 ± 3.6$^a$ | 1.51 ± 0.33$^a$ |
| CdCl$_2$ + Cur 50 mg/kg  | 32.2 ± 2.9$^{a,b}$ | 1.24 ± 0.4$^{a,b}$ |
| CdCl$_2$ + Cur 100 mg/kg | 30.3 ± 2.5$^{a,b}$ | 1.21 ± 0.33$^{a,b}$ |
| CdCl$_2$ + Re 20 mg/kg  | 26.6 ± 3.1$^{a,b}$ | 1.02 ± 0.37$^{a,b}$ |
| CdCl$_2$ + BJe 20 mg/kg | 34.3 ± 2.1$^{a,b}$ | 1.29 ± 0.28$^{a,b}$ |
| CdCl$_2$ + BJe 40 mg/kg | 18.3 ± 1.9$^b$ | 0.77 ± 0.29$^b$ |
| CdCl$_2$ + Cur 50 mg/kg + Re 20 mg/kg + BJe 20 mg/kg | 15.9 ± 1.6$^b$ | 0.73 ± 0.18$^b$ |
| CdCl$_2$ + Cur 100 mg/kg + Re 20 mg/kg + BJe 40 mg/kg | 14.7 ± 1.9$^b$ | 0.71 ± 0.15$^b$ |

$^a$ $p < 0.05$ vs. controls; $^b$ $p < 0.05$ vs. CdCl$_2$ + vehicle.

3.2. Effects of Nutraceuticals on GSH and GPx Levels

It is known that in biological system, Cd induces oxidative stress by intracellular GSH depletion or by inhibiting antioxidant enzymes, such as GPx. The results of our study, suggested that as for urea nitrogen and creatinine content, no significant differences in GSH and GPx levels were present between all control groups; therefore, a single value is indicated for controls (Table 3). A significant decrease in GSH and GPx levels was observed in CdCl$_2$-challenged mice ($p < 0.05$). In animals treated with Cur, Re and BJe and challenged with CdCl$_2$, GSH and GPx levels were higher compared to controls mice, being almost superimposable to control mice in those treated with BJe (40 mg/kg) and with both associations (CdCl$_2$ + Cur 50 mg/kg + Re 20 mg/kg + BJe 20 mg/kg and CdCl$_2$ + Cur 100 mg/kg + Re 20 mg/kg + BJe 40 mg/kg) (Table 3).

Table 3. Effects on glutathione (GSH) content and glutathione peroxidase (GPx) activity in control mice, in cadmium chloride (CdCl$_2$; 2 mg/kg i.p.) plus vehicle exposed mice and in mice exposed to CdCl$_2$ (2 mg/kg i.p.) co-administered with curcumin (Cur), resveratrol (Re), bergamot juice extract (BJe), or their combinations. All values are expressed as mean $\pm$ SE; $n=7$ animals for each group.

| Treatment | GSH (µmol/g of Tissue) | GPx (nmol/min per mg of Protein) |
|-----------|------------------------|---------------------------------|
| Controls  | 65 ± 4 $^a$           | 34.6 ± 1.9 $^a$                |
| CdCl$_2$ + vehicle | 47 ± 5 $^a$ | 16.3 ± 1.6 $^a$  |
| CdCl$_2$ + Cur 50 mg/kg  | 53 ± 3 $^a$ | 21.4 ± 0.8 $^a$  |
| CdCl$_2$ + Cur 100 mg/kg | 54 ± 6 $^{a,b}$ | 22.7 ± 0.7$^{a,b}$ |
| CdCl$_2$ + Re 20 mg/kg  | 57 ± 4 $^{a,b}$ | 26.6 ± 1.1$^{a,b}$ |
| CdCl$_2$ + BJe 20 mg/kg | 51 ± 3 $^{a,b}$ | 19.5 ± 1.2$^{a,b}$ |
| CdCl$_2$ + BJe 40 mg/kg | 59 ± 5 $^b$ | 30.3 ± 0.4$^b$ |
| CdCl$_2$ + Cur 50 mg/kg + Re 20 mg/kg + BJe 20 mg/kg | 62 ± 6 $^b$ | 32.2 ± 1.1$^b$ |
| CdCl$_2$ + Cur 100 mg/kg + Re 20 mg/kg + BJe 40 mg/kg | 64 ± 5 $^b$ | 34.1 ± 1.1$^b$ |

$^a$ $p < 0.05$ vs. controls; $^b$ $p < 0.05$ vs. CdCl$_2$ + vehicle.

3.3. Effects of Nutraceuticals on Apoptosis-Related Genes

It is well-recognized that both oxidative and inflammatory pathways started by Cd may induce apoptosis, which plays a key role in Cd-caused nephrotoxicity. Therefore, in our study we evaluated the involvement of apoptosis-related genes in kidney of mice exposed to CdCl$_2$ with or without nutraceuticals. No significant difference was observed in mRNA levels of tp53, Bax, and Bcl2 among the control groups, therefore only one value is indicated for controls. Important changes in tp53, Bax and Bcl2 genes were observed in the kidneys of CdCl$_2$-treated mice compared to control groups. Moreover, the upregulation
of tp53 and Bax found in CdCl₂-challenged mice were hampered by Cur, Re, and BJe, as well as by their associations (Figure 2). In addition, the downregulation of Bcl2 observed in CdCl₂-subjected animals were significantly counteracted by Cur, Re, and BJe, along with their associations (Figure 2).

**Figure 2.** Real-time PCR analysis for tp53 (A), Bax (B) and Bcl2 (C). * p < 0.05, ** p < 0.01 and *** p < 0.001 vs. control mice; § p < 0.05, §§ p < 0.01 and §§§ p < 0.001 vs. CdCl₂-treated mice.

3.4. Effects of Nutraceuticals on Nos2 and Il1b Gene Expression

The high production of iNOS exerts nephrotoxic injury, which in turn can be responsible for the initiation and progression of kidney tubulo-interstitial illness. Therefore, we evaluated the genes level of Nos2, along with Il1b, a key marker of inflammation, that represent a pathogenic event associated with Cd exposure. As shown in Figure 3, a significant upregulation of Nos2 and Il1b were observed in CdCl₂-challenged mice when compared to control animals. Notably, a reduction of their mRNA levels was found in the kidneys of all groups treated with Cur, Re and BJe compared to those from Cd-challenged mice. This reduction was significant in the kidney of mice treated with Re 20 mg/kg and BJe 40 mg/kg, reaching the maximum extent when animals were treated with both Cur 50 mg/kg + Re 20 mg/kg + BJe 20 mg/kg and Cur 100 mg/kg + Re 20 mg/kg + BJe 40 mg/kg (Figure 3).

3.5. Effects of Nutraceuticals on Nrf2, Nqo1 and Hmox1 Gene Expression

Nrf2 is a crucial transcription factor that induces the expression of cellular defense enzymes to counteract oxidative stress, such as Nqo1 and Hmox1. Data of Real-time PCR analyses showed a significant up-regulation of Nrf2, Nqo1 and Hmox1 gene expression in CdCl₂-challenged mice when compared to control animals (Figure 4). In particular, the exposure to CdCl₂ enhanced the mRNA levels of Nrf2, Nqo1 and Hmox1 genes in the kidney mice up to 2.1-, 12.8- and 2.8-fold, respectively (p < 0.001; Figure 3). Contrariwise, a significant decrease of Nrf2, Nqo1 and Hmox1 mRNA levels was found in the kidneys of all experimental groups of animals treated with all doses of Cur, Re and BJe compared to those from Cd-challenged mice. This fall was particularly evident in the kidneys of mice.
treated with the highest dose of BJe 40 mg/kg ($p < 0.001$) and both Cur 50 mg/kg + Re 20 mg/kg + BJe 20 mg/kg ($p < 0.001$) and Cur 100 mg/kg + Re 20 mg/kg + BJe 40 mg/kg associations ($p < 0.001$) (Figure 4).

![Figure 3](image_url)

**Figure 3.** Real-time PCR analysis of Nos2 (A) and Il1b (B). **$p < 0.01$ and *** $p < 0.001$ vs. control mice; $^5$ $p < 0.05$, $^8$ $p < 0.01$ and $^{88}$ $p < 0.001$ vs. CdCl$_2$-treated mice.

![Figure 4](image_url)

**Figure 4.** Real-time PCR analysis of Nrf2 (A), Nqo1 (B) and Hmox1 (C). *** $p < 0.001$ vs. control mice; $^{88}$ $p < 0.001$ vs. CdCl$_2$-treated mice.
3.6. Histological and Morphometric Evaluation

For histological evaluation, kidney sections stained with HE and PAS were examined (Figures 5 and 6). In kidney sections of all control groups stained with HE, glomeruli and tubules showed normal histological organization (a single micrograph is provided for all controls; Figure 4A). In CdCl₂-challenged mice, glomeruli with enlarged Bowman’s spaces, tubules with epithelial damages and interstitial edema were observed (Figure 5B). In mice challenged with CdCl₂ with Cur at both doses, cellular lesions and interstitial edema were reduced (Figure 5C,D). In re-treated CdCl₂-challenged mice, a good preservation of glomeruli was observed, even if some damaged tubules were present (Figure 5E). In CdCl₂-treated mice, BJe alone at both doses of 20 mg/kg or 40 mg/kg, showed protection of both glomeruli and tubules, even if to a different extent (Figure 5F,G). Similarly, both associations (Cur 50 mg/kg + Re 20 mg/kg + BJe 20 mg/kg and Cur 100 mg/kg + Re 20 mg/kg + BJe 40 mg/kg), demonstrated a well-evident protective action against CdCl₂, being glomerular and tubular morphology close to normal (Figure 5H,I). The morphometric evaluation of the glomerular area demonstrated a significant higher surface in CdCl₂-challenged mice, when compared to control groups and a progressive reduction in all the examined groups, with the exception of BJe at lower dose (Figure 5J). When kidney sections were stained with PAS, the proximal tubules of all control groups showed a regular and well stained brush border (a single micrograph is provided for controls; Figure 6A). On the contrary, in CdCl₂-challenged mice, the brush border was thin or absent (Figure 6B). In CdCl₂-challenged mice administered with Cur at both doses, tubules showed a more PAS-positive brush border if compared to CdCl₂ alone (Figure 6C,D). A similar pattern was observed in Re-treated animals (Figure 6E). In mice treated with BJe, the lower dose (20 mg/kg) showed a reduced PAS-positivity, while the brush border was better preserved with the higher dose (40 mg/kg) (Figure 6F,G). The morphological pattern in mice treated with both the associations (Cur 50 mg/kg + Re 20 mg/kg + BJe 20 mg/kg and Cur 100 mg/kg + Re 20 mg/kg + BJe 40 mg/kg) was close to normal (Figure 6H,I). The morphometric evaluation of the tubular damage demonstrated significantly higher scores in CdCl₂-challenged mice, when compared to control groups, and a progressive reduction of the scores in all the examined groups, with the exception of BJe at lower dose (Figure 6J).

3.7. Immunohistochemistry for IL-1β and Nrf2

IL-1β immunoreactivity was undetectable in all control groups; therefore, a single micrograph is provided as representative of all controls (Figure 7A). In CdCl₂ plus vehicle treated mice, almost all tubules displayed a strong IL-1β immunoreactivity (Figure 7B). In mice treated with CdCl₂ plus both doses of Cur or CdCl₂ plus Re, a moderate IL-1β immunoreactivity was present in some tubules (Figure 7C–E). In CdCl₂ plus BJe at the lower dose challenged mice, IL-1β immunoreactivity was milder if compared to CdCl₂ alone treated mice, but higher in respect to Cur and Re (Figure 7F). In mice treated with CdCl₂ plus BJe at 40 mg/kg and with CdCl₂ plus both associations, IL-1β immunoreactivity was similar to controls (Figure 7G–I). The quantitative assessment of IL-1β expression revealed significant lower values (high immunoreactivity) in the 0–255 grayscale in CdCl₂ treated mice vs. controls and a progressive reduction of the optical density (low immunoreactivity), milder only for BJe at the lower dose (Figure 7J).

Nrf2 immunoreactivity was high in all control groups; therefore, a single micrograph is provided to show the morphological pattern of all controls (Figure 8A). In CdCl₂ plus vehicle treated mice, Nrf2 immunoreactivity was absent nearly in all the tubules (Figure 8B). When mice were treated with CdCl₂ plus both doses of Cur or CdCl₂ plus Re, Nrf2 immunoreactivity showed a moderate pattern in some tubules (Figure 8C–E). In mice challenged with CdCl₂ plus BJe at the lower dose, Nrf2 immunoreactivity was lower if compared to Cur and Re (Figure 8F). Instead, mice treated with CdCl₂ plus BJe at 40 mg/kg and plus both associations demonstrated Nrf2 immunoreactivity similar to controls (Figure 8G–I). The quantitative assessment of Nrf2 tubular expression demonstrated significant higher values (low immunoreactivity) in the 0–255 grayscale in CdCl₂
challenged mice versus controls and lower values (high immunoreactivity) in all groups, with the exception of CdCl$_2$ plus BJe at the lower dose of 20 mg/kg (Figure 8J).

Figure 5. Histological organization of the kidneys examined with hematoxylin-eosin stain. (A) Control mice. The normal structure of both tubules and glomeruli is evident. (B) Mice challenged with CdCl$_2$. An irregular organization of glomeruli, evident changes of the tubular epithelium (arrow) and interstitial edema (asterisk) are present. (C,D) Mice challenged with CdCl$_2$ and treated with Cur at 50 or 100 mg/kg. Tubules show epithelial cells with cytoplasmic changes (arrow) and interstitial edema (asterisk). (E) Kidney of CdCl$_2$ plus Re treated mice. Some tubules are lined by epithelial cells with altered morphology (arrow). Extra-tubular edema is reduced (asterisk). (F) Kidney of CdCl$_2$ plus BJe at 20 mg/kg treated mice. The number of damaged tubules (arrow) is increased if compared to Re-treated mice. (G–I) kidneys from mice treated with CdCl$_2$ plus BJe alone at 40 mg/kg and with both the associations Cur 50 mg/kg + Re 20 mg/kg + BJe 20 mg/kg and Cur 100 mg/kg + Re 20 mg/kg + BJe 40 mg/kg. In all groups, the tubules have a normal structure and no edema is present in the interstitial compartment (J) quantitative evaluation of the mean glomerular area in the different groups of mice. * $p < 0.05$ vs. control; § $p < 0.05$ vs. CdCl$_2$-treated mice. Scale bar: 50 µm.
Figure 6. Tubular brush border of the kidneys treated with PAS stain. (A) In control mice the proximal tubules show a regular and evident brush border. (B) In CdCl₂-challenged mice, the brush border is particularly thin or absent (arrow) and structural changes are present in the tubular epithelium. (C,D) Mice challenged with CdCl₂ and treated with Cur at 50 or 100 mg/kg. Some tubules show lack of staining with PAS (arrow) and damaged epithelial cells, other show a normal structure (asterisk). (E) Kidney of CdCl₂ plus Re treated mice. The number of tubules lined by epithelial cells with altered morphology is reduced (arrow). (F) Kidney of CdCl₂ plus BJe at 20 mg/kg treated mice. Tubules negative to PAS stain and with damaged cells (arrow) is increased if compared to Re treated mice. (G–I) Kidneys from mice treated with CdCl₂ plus BJe alone at 40 mg/kg and with both the extract associations Cur 50 mg/kg + Re 20 mg/kg + BJe 20 mg/kg and Cur 100 mg/kg + Re 20 mg/kg + BJe 40 mg/kg. In all groups, the brush border and the tubules have normal organization. (J) Tubular damage score based on the brush border behavior. * p < 0.05 vs. control; § p < 0.05 vs. CdCl₂ plus vehicle. Scale bar: 50 µm.
3.7. Immunohistochemistry for IL-1β and Nrf2

IL-1β immunoreactivity was undetectable in all control groups; therefore, a single micrograph is provided as representative of all controls (Figure 7A).

In CdCl₂ plus vehicle-treated mice, nearly all tubules displayed a strong IL-1β immunoreactivity (Figure 7B).

In mice treated with CdCl₂ plus both doses of Cur and with CdCl₂ plus Re, a moderate IL-1β immunoreactivity was present in some tubules (arrow) (Figures 7C–E).

In CdCl₂ plus BJe at the lower dose challenged mice, IL-1β immunoreactivity (arrow) was milder if compared to CdCl₂ alone treated mice, but higher respect to Cur and Re (Figure 7F).

In mice treated with CdCl₂ plus BJe at 40 mg/kg and with CdCl₂ plus both associations, IL-1β immunoreactivity was absent, similar to controls (Figures 7G–I).

The quantitative assessment of IL-1β expression revealed significant lower values (high immunoreactivity) in the 0–255 grayscale in CdCl₂ treated mice vs. controls and a progressive reduction of the optical density (low immunoreactivity), milder only for BJe at the lower dose (Figure 7J).

**Figure 7.** Immunohistochemical localization of IL-1β in the kidneys. (A) In all control groups, no IL-1β immunoreactivity can be demonstrated. (B) In CdCl₂ plus vehicle-treated mice, nearly all tubules showed a strong IL-1β immunoreactivity (arrow). (C–E) In mice treated with CdCl₂ plus both doses of Cur and with CdCl₂ plus Re, a moderate IL-1β immunoreactivity was present in some tubules (arrow). (F) In CdCl₂ plus BJe at the lower dose challenged mice, IL-1β immunoreactivity (arrow) was milder if compared to CdCl₂ alone treated mice, but higher respect to Cur and Re. (G–I) In mice treated with CdCl₂ plus BJe at 40 mg/kg and with CdCl₂ plus both associations, IL-1β immunoreactivity was absent, similar to controls. (J) Morphometric results for IL-1β expression. Data are expressed in Optical Units/Unit Area (OU/UA) (from 0 = black to 255 = white). * p < 0.05 vs. control; § p < 0.05 vs. CdCl₂ plus vehicle. Scale bar: 50 µm.
Figure 8. Immunohistochemical localization of Nrf2 in the kidneys. (A) In all control groups, Nrf2 immunoreactivity is particularly strong in the tubular wall (arrow). (B) In CdCl₂ plus vehicle-treated mice, no Nrf2 immunoreactivity is present. (C–E) In mice treated with CdCl₂ plus both doses of Cur and with CdCl₂ plus Re, Nrf2 shows a moderate positivity in some tubules (arrow). (F) In mice challenged with CdCl₂ plus BJe at the lower dose, Nrf2 immunoreactivity was lower (arrow) when compared to Cur and Re. (G–I) Mice treated with CdCl₂ plus BJe at 40 mg/kg and with CdCl₂ plus both associations: Nrf2 immunoreactivity is high (arrow), similar to controls. (J) Morphometric results for Nrf2 expression. Data are expressed in optical units/unit area (OU/UA) (from 0 = black to 255 = white). *p < 0.05 vs. control; §p < 0.05 vs. CdCl₂ plus vehicle. Scale bar: 50 µm.

4. Discussion

Cadmium pollution is rising worldwide because of intensified industrial activities, that have increased its availability, and its significant environmental persistency. The role of cadmium in physiological processes is not yet fully understood; however, it competes with...
other essential metal ions, thereby disrupting cell functions. It causes damage to various organs in mammals by causing teratogenicity, genotoxicity, osteoporosis, neurotoxicity and nephrotoxicity [32].

In this study, we observed high values of serum creatinine and blood urea nitrogen of mice exposed to Cd, demonstrating the kidney injury induced by this metal. Levels of these parameters, as well as urine analysis, are often employed as biomarkers for the evaluation of kidney function, despite their limitations for the detection of early stages of kidney diseases [53]. Urea is the major nitrogenous end product of protein and amino acid catabolism. Increased blood urea nitrogen is acknowledged to be associated with kidney disease or failure, blockage of the urinary tract by kidney stones, congestive heart failure, dehydration, fever, shock and bleeding in the digestive tract [54]. Creatinine is a nitrogenous compound formed by creatine and phosphocreatine during muscular metabolism and primarily eliminated through glomerular filtration. It is commonly used as measure of kidney function. We demonstrated that Cur, Re and BJe administration, alone or in combination, reversed Cd-induced nephrotoxicity by reducing the elevated levels of creatinine and blood urea nitrogen in the serum of Cd-treated mice reaching the maxim effect with BJe 40 mg/kg and with both association Cur 50 mg/kg + Re 20 mg/kg + BJe 20 mg/kg and Cur 100 mg/kg + Re 20 mg/kg + BJe 40 mg/kg. This finding was in accordance with previous research showing the improvement of nephrotoxicity by Cur and Re in other experimental models [55,56].

As known, cadmium induces oxidative stress by altering the pro-oxidant/antioxidant balance in animal tissues. In biological systems, Cd does not undergo redox reactions, but it can induce oxidative stress by intracellular GSH depletion [57] or by inhibiting antioxidant enzymes, such as GPx, interacting with their thiol groups [58]. Previous studies demonstrated that GSH depletion enhances Cd-induced hepatotoxicity and that GSH precursor N-acetylcysteine prevents Cd-induced oxidative stress and toxicity in the liver and brain of Cd-exposed rats [59]. These data have been recently confirmed by Zhang and co-workers that demonstrated the protective effects of Re in Cd-induced nephrotoxicity, mitigating GSH depletion and restoring the activity of antioxidant enzymes [60].

In this study, administration of Cd led to oxidative stress which is evidenced by reduced levels of the antioxidant enzymes GPx and GSH that was significantly restored by Cur, Re and BJe, alone or in association.

Furthermore, Cd induces the inducible form of nitric oxide synthase (iNOS), responsible for nitrosative stress. The level of iNOS is very low in healthy kidney [61] and, when produced in large amount, it exerts nephrotoxic injury, with proximal tubules and glomeruli dysfunction in different experimental models, such as renal ischemia/reperfusion [62]. CdCl₂-treated mice showed an enhanced expression of iNOS in renal tissue compared to controls, which could be related to the generation of ROS, secondary to the structural lesions of tubular epithelial cells. In our study, we observed that both the combination of Cur 50 mg/kg + Re 20 mg/kg + BJe 20 mg/kg and Cur 100 mg/kg + Re 20 mg/kg + BJe 40 mg/kg showed a significant positive action against iNOS expression.

Inflammation is a key pathogenic event associated with Cd exposure [63,64], which is responsible of the initiation and progression of kidney tubulo-interstitial illness [18]. It amplifies the expression of pro-inflammatory and transcriptional factors including tumor necrosis factor alfa (TNF-α), IL-1β and iNOS. In our study, both the expression and the immunohistochemical analysis of IL-1β after Cd challenge were increased, thus explaining its detrimental role in the proximal tubules. Recently, we and other demonstrated the efficacy of several natural extracts and compounds in modulating inflammatory process induced by Cd challenge through the reduction of inflammatory markers expression in the kidney [17,18,61,65,66]. In this study, all the examined nutraceuticals and both the associations reduced the expression and the immunohistochemical analysis of IL-1β decreasing the inflammatory damages induced by Cd. These biochemical and molecular data were confirmed by the histopathological examinations, which demonstrated an increased glomerular area, a reduced PAS stain of the proximal tubules brush border, the presence of
tubular cells lesions and of interstitial edema, as already demonstrated in previous observations [17,18]. We demonstrated that Cur and Re reduced cellular lesions and interstitial edema, as well as we observed a more PAS-positive brush border of tubules if compared to CdCl₂. Moreover, BJe alone at both doses, showed protection of both glomeruli and tubules, despite to a different extent. However, BJe at lower dose did not reduce the surface of glomerular area. In addition, BJe at the lower dose showed a reduced PAS-positivity, while the brush border was better preserved with the higher dose. Interestingly, both the associations (Cur 50 mg/kg + Re 20 mg/kg + BJe 20 mg/kg and Cur 100 mg/kg + Re 20 mg/kg + BJe 40 mg/kg), demonstrated a well evident protective action against CdCl₂, being glomerular and tubular morphology close to normal. Moreover, the morphological pattern in mice treated with both the associations was similar to that of the controls. The morphometric evaluation of the tubular damage demonstrated significantly higher scores in CdCl₂-challenged mice, when compared to control groups, and a progressive reduction of the scores in all the examined groups, with the exception of BJe at lower dose.

It is well-acknowledged that both oxidative and inflammatory pathways triggered by Cd may activate apoptosis which plays a pivotal role in Cd-caused nephrotoxicity [67]. Previous studies reported that the occurrence of apoptosis involves p53 and its downstream targets, and that the anti- and pro-apoptotic members of the Bcl-2 family are crucial effectors for p53-regualted apoptosis [68]. In this study, we found that Cd exposure augmented apoptosis in the kidneys. In mice, it was demonstrated that Bcl-2 expression is downregulated and Bax up-regulated after exposure to Cd [69]. Similar results, together with the upregulation of p53, were observed in our research, thus confirming an important role of Cd in triggering apoptosis. In this context, many natural substances have shown a promising role in positively modulating the apoptotic pathways after Cd treatment, such as selenium [70], Potentilla anserina polysaccharide [71], betulinic acid [72], myo-inositol [18], vitamin E [73], quercetin [66]. In our study, we observed that Cur, Re and BJe protected against Cd-induced apoptosis, even if both the association Cur 50 mg/kg + Re 20 mg/kg + BJe 20 mg/kg and Cur 100 mg/kg + Re 20 mg/kg + BJe 40 mg/kg) provided better defense against apoptotic process.

In the last decade, several studies suggested that disruption of the Nrf2 signaling pathway was involved in several kidney diseases [74–76]. Nrf2 is a crucial transcription factor that plays a pivotal role in inducing the expression of cellular defense enzymes to counteract oxidative stress. Physiologically, Nrf2 assembles cytosolic Kelch-like ECH associated protein-1 (Keap1). In response to the oxidative stress injury, Nrf2 translocates into the nucleus, binding to a highly conserved enhancer antioxidant responsive element (ARE) and regulating transcription of a different of phase II metabolism and detoxification genes, such as heme oxygenase 1 (HO-1) and NQO1. Briefly, the Nrf2-regulated antioxidant response serves to contrast oxidative injury and to preserve intracellular redox homeostasis. In this study, we observed a significant up-regulation of Nrf2 gene in kidney of Cd-treated mice. As consequence, the expression levels of downstream Nrf2 signaling genes Hmox1 and Nqo1 were up-regulated. Our results are clearly consistent with previous research, wherein the administration of Cd significantly increased the expression of Nrf2 and further upregulated the expression of downstream phase II detoxification enzymes [77,78]. This result further confirms that Nrf2-ARE signaling is a crucial regulator for cells to maintain the oxidant/antioxidant balance. Finally, as expected, the results showed that pre-treatment with BJe, Cur or Re alone, or in combination (Cur 50 mg/kg + Re 20 mg/kg + BJe 20 mg/kg and Cur 100 mg/kg + Re 20 mg/kg + BJe 40 mg/kg) inhibited the Cd-activated Nrf2 signaling pathway.

5. Conclusions

In conclusion, for the first time, the results of our study suggest that BJe reduces CdCl₂-induced oxidative damage in the kidneys of challenged mice. It significantly improved the impaired renal functionality, along with reducing morphological changes of glomeruli and proximal tubules, which are known as key targets for Cd nephrotoxicity. Moreover,
BJe restored GSH content and GPx activity, counteracted Nos2 and Il1b over-expression and hampered kidney damage through a mechanism involving its anti-apoptotic activity. Finally, BJe was able to modulate the Nrf2 pathway and its downstream signaling genes Hmox1 and Nqo1, increased by CdCl2.

Generally, each nutraceutical is employed alone to achieve the desired outcome; however, in the recent past, we as others [79–81] have highlighted the relevance of a multitarget pharmacological strategy to deal with a disease. Indeed, pathologies are multifactorial events which hence require the necessity to aim at different targets simultaneously.

On this line, we indicated the effectiveness of BJe, likely due to being a phytocom-plex, and that also the association with Cur and Re, well-known bioactive principles, amplify the protective effect of BJe, thus being the first to focus on the combination of nutraceuticals to test their effects to protect renal functions after exposition to environmental toxicants. Our results need to be also proven in clinical studies to definitively assure our statements, although they offer a solid foundation for a new strategy to fight heavy metal toxicity.

Author Contributions: Conceptualization, A.M. (Antonio Micali), M.N. and L.M.; Data Curation, S.C., A.M. (Alessandro Maugeri), A.M. (Antonio Micali), H.R.M., D.P., G.S., J.F. and N.I.; Formal Analysis, A.M. (Alessandro Maugeri), A.M. (Antonio Micali), H.R.M., D.P., G.S., J.F. and N.I.; Writing—Original Draft, S.C.; Writing—Review and Editing, F.S., G.P., M.N. and L.M. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: All procedures were approved by the Italian Ministry of Health (authorization number 112/2017-PR) and by the Institutional Animal Care and Use Committee of the University Hospital of Messina, Messina, Italy. The standards for care and use of animal subjects as stated in the ARRIVE (Animal Research: Reporting In Vivo Experiments) guidelines were followed.

Informed Consent Statement: Not applicable.

Data Availability Statement: The datasets generated for this study are available on request to the corresponding author.

Acknowledgments: A PON Industrial PhD fellowship from the Italian Minister of Instruction, University and Research (MIUR) to Alessandro Maugeri (code: DOT1314952; CUP: J98G18000040007) is gratefully acknowledged.

Conflicts of Interest: All the authors declare no conflict of interest.

References
1. Yang, Q.Z.; Hao, J.; Chen, M.X.; Li, G. Dermatopontin is a novel regulator of the CdCl2-induced decrease in claudin-11 expression. *Toxicol. In Vitro* 2014, 28, 1158–1164. [CrossRef] [PubMed]
2. Babaknejad, N.; Moshtaghie, A.A.; Nayeri, H.; Hani, M.; Bahrami, S. Protective role of zinc and magnesium against cadmium nephrotoxicity in male wistar rats. *Biol. Trace Elem. Res.* 2016, 174, 112–120. [CrossRef] [PubMed]
3. Brzoska, M.M.; Kaminski, M.; Dziki, M.; Moniuszko-Jakoniuk, J. Changes in the structure and function of the kidney of rats chronically exposed to cadmium. II. Histoenzymatic studies. *Arch. Toxicol.* 2004, 78, 226–231. [PubMed]
4. Genchi, G.; Sinicropi, M.S.; Lauria, G.; Carocci, A.; Catalano, A. The effects of cadmium toxicity. *Int. J. Environ. Res. Public Health* 2020, 17, 3782. [CrossRef] [PubMed]
5. Rahman, M.T.; Haque, N.; Abu Kasim, N.H.; De Ley, M. Origin, function, and fate of metallothionein in human blood. *Rev. Physiol. Biochem. Pharmacol.* 2017, 173, 41–62. [CrossRef] [PubMed]
6. Morales, A.I.; Vicente-Sanchez, C.; Sandoval, J.M.; Egido, J.; Mayoral, P.; Arevalo, M.A.; Fernandez-Tagarro, M.; Lopez-Novoa, J.M.; Perez-Barriceno, F. Protective effect of quercetin on experimental chronic cadmium nephrotoxicity in rats is based on its antioxidant properties. *Food Chem. Toxicol.* 2006, 44, 2092–2100. [CrossRef]
7. Ansari, M.A.; Raish, M.; Ahmad, A.; Alkharfy, K.M.; Ahmad, S.F.; Atta, S.M.; Alsaaed, A.M.S.; Bakheet, S.A. Sinapic acid ameliorate cadmium-induced nephrotoxicity: In vivo possible involvement of oxidative stress, apoptosis, and inflammation via NF-kappaB downregulation. *Environ. Toxicol. Pharmacol.* 2017, 51, 100–107. [CrossRef]
8. Thevenod, F. Cadmium and cellular signaling cascades: To be or not to be? *Toxicol. Appl. Pharmacol.* 2009, 238, 221–239. [CrossRef]
9. Gobe, G.; Crane, D. Mitochondria, reactive oxygen species and cadmium toxicity in the kidney. *Toxicol. Lett.* 2010, 198, 49–55. [CrossRef]
10. Prozialeck, W.C.; Edwards, J.R. Mechanisms of cadmium-induced proximal tubule injury: New insights with implications for biomonitoring and therapeutic interventions. *J. Pharmcol. Exp. Ther.* 2012, 343, 2–12. [CrossRef]

11. Fouad, A.A.; Jresat, I. Protective effect of telmisartan against cadmium-induced nephrotoxicity in mice. *Life Sci.* 2011, 89, 29–35. [CrossRef] [PubMed]

12. Flora, S.J.; Pachauri, V. Chelation in metal intoxication. *Int. J. Environ. Res. Public Health* 2010, 7, 2745–2788. [CrossRef] [PubMed]

13. Das, S.; Dewanjee, S.; Dua, T.K.; Joardar, S.; Chakraborty, P.; Bhowmick, S.; Saha, A.; Bhattacharjee, S.; De Feo, V. Carnosic acid attenuates cadmium induced nephrotoxicity by inhibiting oxidative stress, promoting Nrf2/HO-1 signalling and impairing TGF-BETA1/smads/collagen IV signalling. *Molecules* 2019, 24, 4176. [CrossRef]

14. Mohamed, H.R.H. Alleviation of cadmium chloride-induced acute genotoxicity, mitochondrial DNA disruption, and ROS generation by chocolate coadministration in Mouse Liver and Kidney Tissues. *Biol. Trace Elem. Res.* 2021. [CrossRef] [PubMed]

15. Nazima, B.; Manoharan, V.; Miltonprabu, S. Grape seed proanthocyanidins ameliorates cadmium-induced renal injury and oxidative stress in experimental rats through the up-regulation of nuclear related factor 2 and antioxidant responsive elements. *Biochem. Cell Biol. Biochem. Biol. Cell.* 2015, 93, 210–226. [CrossRef]

16. Luo, T.; Liu, G.; Long, M.; Yang, J.; Song, R.; Wang, Y.; Yuan, Y.; Bian, J.; Liu, X.; Gu, J.; et al. Treatment of cadmium-induced renal oxidative damage in rats by administration of alpha-lipoic acid. *Environ. Sci. Pollut. Res. Int.* 2017, 24, 1832–1844. [CrossRef]

17. Micali, A.; Pallio, G.; Irrera, N.; Marini, H.; Trichilo, V.; Puzzolo, D.; Pisani, A.; Malta, C.; Santoro, G.; Laura, R.; et al. Flavonoid, a natural antioxidant, protects mouse kidney from cadmium-induced toxicity. *Oxid. Med. Cell. Longev.* 2018, 2018, 9162946. [CrossRef] [PubMed]

18. Pallio, G.; Micali, A.; Benveniga, S.; Antonelli, A.; Marini, H.R.; Puzzolo, D.; Macaione, V.; Trichilo, V.; Santoro, G.; Irrera, N.; et al. Myo-inositol in the protection from cadmium toxicity in mice: An emerging nutraceutical challenge. *Food Chem. Toxicol.* 2019, 132, 110675. [CrossRef] [PubMed]

19. Mannucci, C.; Navarra, M.; Calapai, F.; Squeri, R.; Gangemi, S.; Calapai, G. Clinical pharmacology of *Citrus bergamia*: A systematic review. *Phytother. Res. PTR* 2017, 31, 27–39. [CrossRef]

20. Marino, A.; Paterniti, I.; Cordaro, M.; Morabito, R.; Campolo, M.; Navarra, M.; Esposito, E.; Cuzzocrea, S. Role of natural antioxidants and potential use of bergamot in treating rheumatoid arthritis. *PharmaNutrition* 2015, 3, 53–59. [CrossRef]

21. Navarra, M.; Femia, A.P.; Romagnoli, A.; Tortora, K.; Luceci, C.; Cirmi, S.; Ferlazzo, N.; Caderni, G. A flavonoid-rich extract from bergamot juice prevents carcinogenesis in a genetic model of colorectal cancer, the Pirc rat (F344/NTac-Apc(amI137)). *Eur. J. Nutr.* 2020, 59, 885–894. [CrossRef] [PubMed]

22. Filocamo, A.; Bisignano, C.; Ferlazzo, N.; Cirmi, S.; Mandalari, G.; Navarra, M. In vitro effect of bergamot (*Citrus bergamia*) juice against cagA-positive and-negative clinical isolates of Helicobacter pylori. *BMC Complement. Altern. Med.* 2015, 15, 256. [CrossRef]

23. Cirmi, S.; Bisignano, C.; Mandalari, G.; Navarra, M. Anti-infective potential of *Citrus bergamia* Risso et Poiteau (bergamot) derivatives: A systematic review. *Phytother. Res. PTR* 2016, 30, 1404–1411. [CrossRef] [PubMed]

24. Mollace, V.; Scicchitano, M.; Paone, S.; Casale, F.; Calandrocco, C.; Glozzi, M.; Musolino, V.; Carressi, C.; Maiuolo, J.; Nucera, S.; et al. Hypoglycemic and hypolipemic effects of a new lecithin formulation of bergamot polyphenolic fraction: A double blind, randomized, placebo-controlled study. *Endocr. Metab. Immune Disord. Drug Targets* 2019, 19, 136–143. [CrossRef]

25. Ferlazzo, N.; Cirmi, S.; Maugeri, A.; Russo, C.; Lombardo, G.E.; Gangemi, S.; Calapai, G.; Mollace, V.; Navarra, M. Neuroprotective effect of bergamot juice in 6-OHDA-induced SH-SY5Y cell death, an in vitro model of parkinson’s disease. *Pharmaceutics* 2020, 12, 326. [CrossRef] [PubMed]

26. Curro, M.; Risitano, R.; Ferlazzo, N.; Cirmi, S.; Gangemi, C.; Caccamo, D.; Gentile, R.; Navarra, M. *Citrus bergamia* juice extract attenuates beta-amyloid-induced pro-inflammatory activation of THP-1 cells through MAPK and AP-1 pathways. *Sci. Rep.* 2016, 6, 20809. [CrossRef]

27. Ferlazzo, N.; Visalli, G.; Smeriglio, A.; Cirmi, S.; Lombardo, G.E.; Campiglia, P.; Di Pietro, A.; Navarra, M. Flavonoid fraction of orange and bergamot juices protect human lung epithelial cells from hydrogen peroxide-induced oxidative Stress. *Evid. Based Complement. Altern. Med. eCAM* 2015, 2015, 957031. [CrossRef]

28. Ferlazzo, N.; Visalli, G.; Cirmi, S.; Lombardo, G.E.; Lagana, P.; Di Pietro, A.; Navarra, M. Natural iron chelators: Protective role in A549 cells of flavonoids-rich extracts of Citrus juices in Fe(3+)-induced oxidative stress. *Environ. Toxicol. Pharmacol.* 2016, 43, 248–256. [CrossRef]

29. Maugeri, A.; Cirmi, S.; Minciullo, P.L.; Gangemi, S.; Calapai, G.; Mollace, V.; Navarra, M. Citrus fruits and inflammaging: A systematic review. *Phytochem. Rev.* 2019, 18, 1025–1049. [CrossRef]

30. Maugeri, A.; Ferlazzo, N.; De Luca, L.; Gitt, R.; Navarra, M. The link between the AMPK/SIRT1 axis and a flavonoid-rich extract of *Citrus bergamia* juice: A cell-free, in silico, and in vitro study. *Phytother. Res.* 2019, 33, 1805–1814. [CrossRef]

31. Musumeci, L.; Maugeri, A.; Cirmi, S.; Lombardo, G.E.; Russo, C.; Gangemi, S.; Calapai, G.; Navarra, M. Citrus fruits and their flavonoids in inflammatory bowel disease: An overview. *Nat. Prod. Res.* 2020, 34, 122–136. [CrossRef]

32. Ferlazzo, N.; Cirmi, S.; Calapai, G.; Ventura-Spagnolo, E.; Gangemi, S.; Navarra, M. Anti-inflammatory activity of *Citrus bergamia* derivatives: Where do we stand? *Molecules* 2016, 21, 1273. [CrossRef] [PubMed]

33. Ferlazzo, N.; Micali, A.; Marini, H.R.; Freni, J.; Santoro, G.; Puzzolo, D.; Squadrito, F.; Pallio, G.; Navarra, M.; Cirmi, S.; et al. A flavonoid-rich extract from bergamot juice, alone or in association with curcumin and resveratrol, shows protective effects in a murine model of cadmium-induced testicular injury. *Pharmaceuticals* 2021, 14, 386. [CrossRef] [PubMed]
34. Park, J.H.; Lee, B.M.; Kim, H.S. Potential protective roles of curcumin against cadmium-induced toxicity and oxidative stress. J. Toxicol. Environ. Health Part B Crit. Rev. 2021, 24, 95–118. [CrossRef]

35. Avila-Rojas, S.H.; Lira-Leon, A.; Aparicio-Trejo, O.E.; Reyes-Fermin, L.M.; Pedraza-Chaverri, J. Role of autophagy on heavy metal-induced renal damage and the protective effects of curcumin in autophagy and kidney preservation. Medicine 2019, 55, 360. [CrossRef] [PubMed]

36. Fu, X.; Li, M.; Tang, C.; Huang, Z.; Najafi, M. Targeting of cancer cell death mechanisms by resveratrol: A review. Apoptosis 2021, 26, 561–573. [CrossRef] [PubMed]

37. Gal, R.; Deres, L.; Toth, K.; Halmosi, R.; Habon, T. The effect of resveratrol on the cardiovascular system from molecular mechanisms to clinical results. Int. J. Mol. Sci. 2022, 21, 10152. [CrossRef]

38. Smoliga, J.M.; Baur, J.A.; Hausenblas, H.A. Resveratrol and health—A comprehensive review of human clinical trials. Mol. Nutr. Food Res. 2011, 55, 1129–1141. [CrossRef] [PubMed]

39. Tabrizi, R.; Tamtaji, O.R.; Lankarani, K.B.; Akbari, M.; Dadgostar, E.; Dabbaghmanesh, M.H.; Kolahdooz, F.; Shamshirian, A.; Momen-Heravi, M.; Asemi, Z. The effects of resveratrol intake on weight loss: A systematic review and meta-analysis of randomized controlled trials. Crit. Rev. Food Sci. Nutr. 2020, 60, 375–390. [CrossRef]

40. Gugliandolo, E.; Fusco, R.; D’Amico, R.; Peditto, M.; Oteri, G.; Di Paola, R.; Cuzzocrea, S.; Navarra, M. Treatment with a flavonoid-rich fraction of bergamot juice improved lipopolysaccharide-induced periodontitis in rats. Front. Pharmacol. 2018, 9, 1563. [CrossRef]

41. Minutoli, L.; Miceli, A.; Pisani, A.; Puzzolo, D.; Bitto, A.; Rinaldi, M.; Pizzino, G.; Irrera, N.; Gallo, F.; Arena, S.; et al. Flavocoxid protects against cadmium-induced disruption of the blood-testis barrier and improves testicular damage and germ cell impairment in mice [corrected]. Toxicol. Sci. 2015, 148, 311–329. [CrossRef]

42. Benvenga, S.; Miceli, A.; Pallio, G.; Vita, R.; Malta, C.; Puzzolo, D.; Irrera, N.; Squadrito, F.; Altavilla, D.; Minutoli, L. Effects of myo-inositol alone and in combination with seleno-l-methionine on cadmium-induced testicular damage in mice. Curr. Mol. Pharmacol. 2019, 12, 311–323. [CrossRef] [PubMed]

43. Eleawa, S.M.; Alkhateeb, M.A.; Alhashem, F.H.; Bin-Jaliah, I.; Sakr, H.F.; Elrefaey, H.M.; Haidara, M.A.; Shatoor, A.S.; et al. Resveratrol reverses cadmium chloride-induced testicular damage and subfertility by downregulating p53 and Bax and upregulating gonadotropins and Bcl-2 gene expression. J. Reprod. Dev. 2014, 60, 115–127. [CrossRef] [PubMed]

44. Momeni, H.R.; Eskandari, N. Curcumin protects the testis against cadmium-induced histopathological damages and oxidative stress in mice. Hum. Exp. Toxicol. 2020, 39, 653–661. [CrossRef] [PubMed]

45. Eybl, V.; Kotyzova, D.; Koutensky, J. Comparative study of natural antioxidants—Curcumin, resveratrol and melatonin—In cadmium-induced oxidative damage in mice. Toxicology 2006, 225, 150–156. [CrossRef] [PubMed]

46. Yang, S.H.; He, J.B.; Yu, L.H.; Li, L.; Long, M.; Liu, M.D.; Li, P. Protective role of curcumin in cadmium-induced testicular injury in mice by attenuating oxidative stress via Nrf2/ARE pathway. Environ. Sci. Pollut. Res. Int. 2019, 26, 34575–34583. [CrossRef] [PubMed]

47. Gong, P.; Chen, F.; Liu, X.; Gong, X.; Wang, J.; Ma, Y. Protective effect of caffeic acid phenethyl ester against cadmium-induced renal damage in mice. J. Toxicol. Sci. 2012, 37, 415–425. [CrossRef] [PubMed]

48. Flohe, L.; Gunzler, W.A. Assays of glutathione peroxidase. Methods Enzymol. 1984, 105, 114–121. [CrossRef]

49. Manna, P.; Sinha, M.; Sil, P.C. Taurine plays a beneficial role against cadmium-induced oxidative renal dysfunction. Amino Acids 2009, 36, 417–428. [CrossRef]

50. Yamamoto, Y.; Maeshima, Y.; Kitamura, S.; Takazawa, Y.; Sugiyama, H.; Yamasaki, Y.; Makino, H. Tumstatin, a peptide, an inhibitor of angiogenesis, prevents glomerular hypertrophy in the early stage of diabetic nephropathy. Diabetes 2004, 53, 1831–1840. [CrossRef] [PubMed]

51. Okada, H.; Senmaru, T.; Fukui, M.; Kondo, Y.; Ishigami, A.; Maruyama, N.; Obayashi, H.; Yamazaki, M.; Nakamura, N.; Hasegawa, G. Senescence marker protein-30/glucurononatase deficiency exacerbates diabetic nephropathy through tubular injury in a mouse model of type 1 diabetes. J. Diabetes Investig. 2015, 6, 34–43. [CrossRef]

52. Thevenod, F.; Wolff, N.A. Iron transport in the kidney: Implications for physiology and cadmium nephrotoxicity. Met. Integr. Biomet. Sci. 2016, 8, 17–42. [CrossRef] [PubMed]

53. Kostic, D.; Tomic, N.; Radosavljevic, B.; Avramovic, N.; Dragutinovic, V.; Skodric, S.R.; Colovic, M. Biochemical markers of renal function. Curr. Med. Chem. 2016, 23, 2018–2040. [CrossRef] [PubMed]

54. Gowda, S.; Desai, P.B.; Kulkarni, S.S.; Hull, V.V.; Math, A.A.; Vernekar, S.N. Markers of renal function tests. N. Am. J. Med. Sci. 2010, 2, 170–173.

55. Zhao, Y.H.; Shen, C.F.; Wang, G.J.; Kang, Y.; Song, Y.H.; Liu, J.W. Curcumin alleviates acute kidney injury in a dry-heat damage via attenuation of inflammation and oxidative stress in high-fat-diet-induced obese mice. Inflammation 2019, 42, 937–945. [CrossRef] [PubMed]

56. Nemmiche, S. Oxidative signaling response to cadmium exposure. Toxicol. Sci. 2017, 156, 4–10. [CrossRef]

57. Koedrith, P.; Seo, Y.R. Advances in carcinogenic metal toxicity and potential molecular markers. Int. J. Mol. Sci. 2011, 12, 9576–9595. [CrossRef] [PubMed]
59. Tandon, S.K.; Singh, S.; Prasad, S.; Khandekar, K.; Dwivedi, V.K.; Chatterjee, M.; Mathur, N. Reversal of cadmium induced oxidative stress by chelating agent, antioxidant or their combination in rat. *Toxicol. Lett.* 2003, 145, 211–217. [CrossRef] [PubMed]

60. Zhang, Q.; Zhang, C.; Ge, J.; Lv, M.W.; Talukder, M.; Guo, K.; Li, Y.H.; Li, J.L. Ameliorative effects of resveratrol against cadmium-induced nephrotoxicity via modulating nuclear xenobiotic receptor response and PINK1/Parkin-mediated Mitophagy. *Food Funct.* 2020, 11, 1856–1868. [CrossRef] [PubMed]

61. Ansari, M.N.; Rehman, N.U.; Karim, A.; Imam, F.; Hamad, A.M. Protective effect of thymus serrulatus essential oil on cadmium-induced nephrotoxicity in rats, through suppression of oxidative stress and downregulation of NF-kappaB, iNOS, and Smad2 mRNA expression. *Molecules* 2021, 26, 1252. [CrossRef] [PubMed]

62. Chatterjee, P.K. Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: A comprehensive review. *Naunyn-Schmiedeberg's Arch. Pharmacol.* 2007, 376, 1–43. [CrossRef] [PubMed]

63. Rinaldi, M.; Micali, A.; Marini, H.; Adamo, E.B.; Puzzolo, D.; Pisani, A.; Trichilo, V.; Altavilla, D.; Squadrito, F.; Minutoli, L. Cadmium, organ toxicity and therapeutic approaches: A review on brain, kidney and testis damage. *Curr. Med. Chem.* 2017, 24, 3879–3893. [CrossRef] [PubMed]

64. Almeir, R.S.; AlBasher, G.I.; Alarifi, S.; Alkahtani, S.; Ali, D.; Abdel Moneim, A.E. Royal jelly attenuates cadmium-induced nephrotoxicity in male mice. *Sci. Rep.* 2019, 9, 5825. [CrossRef]

65. Osukoya, O.A.; Oyinloye, B.E.; Ajiboye, B.O.; Olokode, K.A.; Adeola, H.A. Nephroprotective and anti-inflammatory potential of aqueous extract from Persea americana seeds against cadmium-induced nephrotoxicity in Wistar rats. *Biometals* 2021, 34, 1141–1153. [CrossRef]

66. Alshammari, G.M.; Al-Qahtani, W.H.; AlFaris, N.A.; Albekairi, N.A.; Alqahtani, S.; Eid, R.; Yagoub, A.E.A.; Al-Harbi, L.N.; Yahya, M.A. Quercetin alleviates cadmium chloride-induced renal damage in rats by suppressing endoplasmic reticulum stress through SIRT1-dependent deacetylation of Xbp-1s and eIF2alpha. *Biomed. Pharmacother.* 2021, 141, 111862. [CrossRef]

67. Kim, K.S.; Lim, H.J.; Lim, J.S.; Son, J.Y.; Lee, J.; Lee, B.M.; Chang, S.C.; Kim, H.S. Curcumin ameliorates cadmium-induced nephrotoxicity in Sprague-Dawley rats. *Food Chem. Toxicol.* 2018, 114, 34–40. [CrossRef] [PubMed]

68. Dashzeveg, N.; Yoshioka, K. Cell death decision by p53 via control of the mitochondrial membrane. *Cancer Lett.* 2015, 367, 108–112. [CrossRef]

69. Mahdavi, S.; Khodarahmi, P.; Roodbari, N.H. Effects of cadmium on Bcl-2/ Bax expression ratio in rat cortex brain and hippocampus. *Hum. Exp. Toxicol.* 2018, 37, 39, 5825. [CrossRef]

70. Wang, Y.; Wu, Y.; Luo, K.; Liu, Y.; Zhou, M.; Yan, S.; Shi, H.; Cai, Y. The protective effects of selenium on cadmium-induced oxidative stress and apoptosis via mitochondria pathway in mice kidney. *Food Chem. Toxicol.* 2013, 58, 61–67. [CrossRef]

71. Shen, R.; Liu, D.; Hou, C.; Liu, D.; Zhao, L.; Cheng, J.; Wang, D.; Bai, D. Protective effect of *Potentilla anserina* polysaccharide on cadmium-induced nephrotoxicity in vitro and in vivo. *Food Funct.* 2017, 8, 3636–3646. [CrossRef]

72. Fan, R.; Hu, P.C.; Wang, Y.; Lin, H.Y.; Su, K.; Feng, X.S.; Wei, L.; Yang, F. Betulinic acid protects mice from cadmium chloride-induced toxicity by inhibiting cadmium-induced apoptosis in kidney and liver. *Toxicol. Lett.* 2018, 299, 56–66. [CrossRef]

73. Fang, J.; Xie, S.; Chen, Z.; Wang, F.; Chen, K.; Zuo, Z.; Cui, H.; Guo, H.; Ouyang, P.; Chen, Z.; et al. Protective effect of Vitamin E on cadmium-induced renal oxidative damage and apoptosis in rats. *Biol. Trace Elem. Res.* 2021, 199, 4675–4687. [CrossRef] [PubMed]

74. Stenvinkel, P.; Chertow, G.M.; Devarajan, P.; Levin, A.; Andreoli, S.P.; Bangalore, S.; Warady, B.A. Chronic inflammation in chronic kidney disease progression: Role of Nrf2. *Kidney Int. Rep.* 2021, 6, 1775–1787. [CrossRef]

75. Schmidlin, C.J.; Dodson, M.B.; Zhang, D.D. Filtering through the role of Nrf2 in kidney disease. *Arch. Pharm. Res.* 2020, 43, 361–369. [CrossRef]

76. Shelton, L.M.; Park, B.K.; Copple, I.M. Role of Nrf2 in protection against acute kidney injury. *Kidney Int.* 2013, 84, 1090–1095. [CrossRef] [PubMed]

77. Wang, X.Y.; Wang, Z.Y.; Zhu, Y.S.; Zhu, S.M.; Fan, R.F.; Wang, L. Alleviation of cadmium-induced oxidative stress by trehalose via inhibiting the Nrf2-Keap1 signaling pathway in primary rat proximal tubular cells. *J. Biochem. Mol. Toxicol.* 2018, 32, e2011. [CrossRef]

78. Yan, L.-J.; Allen, D.C. Cadmium-induced kidney injury: Oxidative damage as a unifying mechanism. *Biomolecules* 2021, 11, 1575. [CrossRef]

79. Cirmi, S.; Maugeri, A.; Ferlazzo, N.; Gangemi, S.; Calapai, G.; Schumacher, U.; Navarra, M. Anticancer potential of citrus juices and their extracts: A systematic review of both preclinical and clinical studies. *Front. Pharmacol.* 2017, 8, 420. [CrossRef] [PubMed]

80. Atanasov, A.G.; Zotchev, S.B.; Dirsch, V.M.; the International Natural Product Sciences Taskforce; Supuran, C.T. Natural products in drug discovery: Advances and opportunities. *Nat. Rev. Drug Discov.* 2021, 20, 200–216. [CrossRef]

81. Efferth, T.; Koch, E. Complex interactions between phytochemicals. The multi-target therapeutic concept of phytotherapy. *Curr. Drug Targets* 2011, 12, 122–132. [CrossRef] [PubMed]